Journal
CNS DRUGS
Volume 36, Issue 7, Pages 703-719Publisher
ADIS INT LTD
DOI: 10.1007/s40263-022-00927-z
Keywords
-
Categories
Funding
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Ask authors/readers for more resources
Siponimod is an approved oral treatment for relapsing forms of multiple sclerosis, which targets the immune response and neural inflammation through regulating S1P(1) and S1P(5) receptors. It reduces lymphocyte migration to the central nervous system and exerts effects on various brain cells to decrease neurodegeneration and damage.
Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P(1)) and 5 (S1P(5)) modulator approved in the United States and the European Union as an oral treatment for adults with relapsing forms of multiple sclerosis (RMS), including active secondary progressive multiple sclerosis (SPMS). Preclinical and clinical studies provide support for a dual mechanism of action of siponimod, targeting peripherally mediated inflammation and exerting direct central effects. As an S1P(1) receptor modulator, siponimod reduces lymphocyte egress from lymph nodes, thus inhibiting their migration from the periphery to the central nervous system. As a result of its peripheral immunomodulatory effects, siponimod reduces both magnetic resonance imaging (MRI) lesion (gadolinium-enhancing and new/enlarging T2 hyperintense) and relapse activity compared with placebo. Independent of these effects, siponimod can penetrate the blood-brain barrier and, by binding to S1P(1) and S1P(5) receptors on a variety of brain cells, including astrocytes, oligodendrocytes, neurons, and microglia, exert effects to modulate neural inflammation and neurodegeneration. Clinical data in patients with SPMS have shown that, compared with placebo, siponimod treatment is associated with reductions in levels of neurofilament light chain (a marker of neuroaxonal damage) and thalamic and cortical gray matter atrophy, with smaller reductions in MRI magnetization transfer ratio and reduced confirmed disability progression. This review examines the preclinical and clinical data supporting the dual mechanism of action of siponimod in RMS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available